ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Publications / Posters

Technology

  • Home
  • Technology
  • Publications / Posters
Technology

Technology

  • Overview
  • Lysins
  • Amurins
  • Publications / Posters
  • Video Library
  • « Previous
  • 1
  • 2
  • 3
Lysin CF-301 Administered in Addition to Vancomycin (VAN) Suppresses the Emergence of Reduced Susceptibilities to VAN Within Cardiac Vegetations in A Rabbit Model of MRSA Infective Endocarditis (IE)

Lysin CF-301 Administered in Addition to Vancomycin (VAN) Suppresses the Emergence of Reduced Susceptibilities to VAN Within Cardiac Vegetations in A Rabbit Model of MRSA Infective Endocarditis (IE)

Presented at ASM 2018, June 10, 2018
Lysin CF-301 Demonstrates Potent in Vitro Activity against a Range of Staphylococcus and Streptococcus Species Associated with Complicated Bacteremia and Infective Endocarditis in Humans

Lysin CF-301 Demonstrates Potent in Vitro Activity against a Range of Staphylococcus and Streptococcus Species Associated with Complicated Bacteremia and Infective Endocarditis in Humans

Presented at ASM 2018, June 10, 2018
CF-301 Activity versus Contemporary Staphylococcus aureus Clinical Isolates from US Hospitals

CF-301 Activity versus Contemporary Staphylococcus aureus Clinical Isolates from US Hospitals

Presented at ASM 2018, June 10, 2018
Lysin CF-301 exhibits a low propensity for decreased susceptibility and prevents daptomycin resistance in a rabbit model of Staph aureus infective endocarditis

Lysin CF-301 exhibits a low propensity for decreased susceptibility and prevents daptomycin resistance in a rabbit model of Staph aureus infective endocarditis

Presented at 28th ECCMID, April 24, 2018
Optimal timing of the Co-administration of lysin CF-301 with daptomycin in a rabbit model of infective endocarditis due to MRSA

Optimal timing of the Co-administration of lysin CF-301 with daptomycin in a rabbit model of infective endocarditis due to MRSA

Presented at 28th ECCMID, April 24, 2018
European surveillance study of CF-301 activity against contemporary Staph aureus isolates from Italy, Greece, and Hungary

European surveillance study of CF-301 activity against contemporary Staph aureus isolates from Italy, Greece, and Hungary

Presented at 28th ECCMID, April 24, 2018
 Translational study of the antibiofilm activity of lysin CF-301 in an infected hemodialysis catheter from patient with suspected Staph aureus bacteremia

Translational study of the antibiofilm activity of lysin CF-301 in an infected hemodialysis catheter from patient with suspected Staph aureus bacteremia

Presented at 28th ECCMID, April 23, 2018
Activity of Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus aureus Clinical Isolates from the USA, Europe and South America

Activity of Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus aureus Clinical Isolates from the USA, Europe and South America

Presented at ID Week 2017, October 6, 2017
Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus

Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus

Presented at ID Week 2017, October 6, 2017
 Population Phamacokinetic-Pharmacodynamic Assessment of Cardiac Safety Endpoints for CF-301, a First-In-Class Antibacterial Lysin

Population Phamacokinetic-Pharmacodynamic Assessment of Cardiac Safety Endpoints for CF-301, a First-In-Class Antibacterial Lysin

Presented at ASM Microbe 2017, June 3, 2017
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next »
© 2023 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter